We recently reported that MLN4924 (pevonedistat), an investigational agent that inhibits the NEDD8-activating enzyme (NAE), abrogates stromal-mediated NF-κB pathway activity and CLL cell survival. This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.